Streetbeat News

Revenues

FAST

Analyst reviews for Fastenal (NASDAQ:FAST) over the past three months show a mix of bullish and indifferent sentiments, with an average 12-month price target of $77.5, up 10.71% from the previous $70.00. Recent actions by analysts from Stifel and Baird include raising price targets, reflecting positive market conditions and company performance. Fastenal's financials indicate strong market position, revenue growth, and efficient cost management, despite challenges in ROE compared to industry averages.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 12:01 pm

DT

In the past three months, 15 analysts have provided diverse ratings for Dynatrace (NYSE:DT), with a recent shift towards more bullish perspectives. The average 12-month price target has risen to $66.67, indicating a 10.51% increase from the previous target. Dynatrace's financial performance shows a 22.74% revenue growth rate and a net margin of 11.69%, although its ROE and ROA are below industry averages. The company's low debt-to-equity ratio suggests a conservative financial strategy.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 12:00 pm

ESS

Essex Property Trust (NYSE:ESS) has received mixed analyst ratings over the past three months, with a total of 11 analysts offering views ranging from bullish to bearish. The average 12-month price target for ESS is $246.18, reflecting a 5.3% increase from the previous target of $233.78. Analyst actions include various ratings and price target adjustments, indicating evolving market conditions and company performance. Essex Property Trust, owning over 62,000 units across 252 apartment communities, shows strong market position, revenue growth, and financial health with a notable ROE of 1.19% and ROA of 0.53%.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 12:00 pm

HPP

A comprehensive analysis of Hudson Pacific Properties (NYSE:HPP) by 7 analysts over the last three months shows diverse opinions, with recent updates indicating an average 12-month price target of $10.79, up 17.54% from the previous $9.18. The analysis includes various rating adjustments and price target changes by analysts from firms like Wolfe Research, Wedbush, Goldman Sachs, BMO Capital, Jefferies, BTIG, and Piper Sandler. Hudson Pacific Properties, a real estate investment trust focusing on office and entertainment properties on the West Coast, faces challenges with a revenue decline of -17.23% and below-average financial metrics compared to the industry.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 12:00 pm

FSR

Fisker is facing significant funding challenges, seeking to raise $166.67 million through convertible notes amid concerns about its ability to continue as a going concern. The company has experienced substantial cash burn, with its cash balance significantly reduced. The funding, structured in four tranches, aims to support Fisker's transition to a dealer model and vehicle sales. However, the company acknowledges the need for additional funding and the possibility of seeking bankruptcy protection if unable to secure necessary capital.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 11:56 am

ABEO

Abeona Therapeutics reported its FY23 financial results, showcasing a significant increase in revenue to $3.50M from $1.41M year-over-year. The company also reduced its EPS loss to $(2.53) from $(5.53) YoY, and reported a cash balance of $52.6M.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 11:35 am

PED

PEDEVCO reported a 43% increase in average daily production to 1,427 barrels of oil equivalent per day (74% oil) in 2023 compared to 2022. The company also reported a 2023 adjusted EBITDA of $17.5M, marking an 8% increase year-over-year.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 11:26 am

PTGX

TAK

Protagonist Therapeutics has finalized a global license and collaboration agreement with Takeda for Rusfertide. Protagonist is set to receive a $300M upfront payment in Q2 2024.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 11:12 am

ERJ

Embraer projects its 2024 revenue to be between $6B-$6.4B, aligning with a $6.21B consensus. The company anticipates an adjusted EBIT margin of 6.5%-7.5% and expects to deliver 72-80 commercial and 125-135 executive aircraft. Additionally, Embraer forecasts an adjusted free cash flow of $220 million or more for the year.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 11:07 am

AZN

AstraZeneca announced a cap on out-of-pocket costs at $35 per month for its inhaled respiratory portfolio in the US, aiming to make these medications more affordable for patients. This move could enhance patient access to essential treatments and potentially increase the usage of AstraZeneca's respiratory products.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 11:02 am